derstands that people living with diabetes can become
more engaged in controlling their disease if they are
supported by coach counselors as well as being given
a blood glucose meter, which allows monitoring of
remote compliance and provides immediate feedback
for the patient. Indeed, they have been able to show
that this integrated approach can reduce claims by an
average of $3,384 vs. a control group of similar diabetes patients8.
What have we learned?
Mobile technology can serve a purpose of improving
outcomes and decreasing costs -- if we remember that
stakeholder engagement is key. Apps and wearables
are a key component of this engagement, and will
only increase in importance especially as the challenges to mHealth reduce over time. However, to be
effective in changing behavior and affecting health
outcomes, they need to be part of a more integrated
cohesive care environment.
So the key questions to be asked, right after someone
has the great idea for an app or wearable, but before
you start designing, are:
• Who are we trying to motivate?
• What do we want them to do?
• What do we know about the triggers that inspire
• How do we get them to perceive the value?
• How does the technology integrate into the health-care environment in order to provide support over
As we noted earlier, factors such as privacy of information and regulatory hurdles are a challenge
to mHealth, but are surmountable. In order to have
greater impact, we need to put the people back into
the equation. Time to think—patient focused activities can change behavior. •
1research2guidance, The mHealth app market (Vol.
2Pew Center Research 2012
4research2guidance (as of March 2014)
5Lowenstein G., Brennan T. and Volpp K. (2007)
Anita Burrell is a market
access pioneer renowned
for promoting multi-
delivering products to launch in advance
of schedule. She has significant breadth of
experience in establishing value evidence
across the top 10 therapeutic areas. Ms.
Burrell has headed multiple divisions at
Sanofi, including Commercial Operations
Effectiveness for Global Diabetes, Distinct
Project Unit Multiple Sclerosis, Health
Economics and Reimbursement, and Health
Outcomes CNS/IM. She has also been
Head of the Teriflunomide/MS Unit at
Genzyme and Manager of Health Economics
at Boehringer Engelheim. Currently serving
as Adjunct Assistant Professor at Rutgers
University, teaching the Health Outcomes,
Policy and Economics Master of Science
course, she is also a leader in the Healthcare
6HRI/CIS Wearables consumer survey 2014
7PwC Health Research Institute Survey 2014
8Javitt et al US Endocrinology 2013
All opinions expressed in this presentation are those of the presenter and are not intended to imply that they reflect the position
of Sanofi. All figures and data provided are available from public
sources available on request.